A molecular signature of disease written in blood before memory fades
Em Hong Kong, pesquisadores da Universidade de Ciência e Tecnologia desenvolveram um exame de sangue capaz de detectar o Alzheimer com 96% de precisão — antes mesmo que qualquer sintoma se manifeste. A doença escreve sua assinatura molecular no sangue anos, às vezes décadas, antes de apagar memórias e identidades. Este avanço não é apenas técnico: é uma inversão do tempo clínico, uma chance de agir enquanto o silêncio ainda é reversível.
- O Alzheimer começa a destruir o cérebro 10 a 20 anos antes de qualquer esquecimento visível — e até agora a medicina só conseguia enxergá-lo tarde demais.
- Diagnósticos definitivos exigiam procedimentos caros e invasivos, tornando a detecção precoce inacessível para a maioria da população mundial.
- Pesquisadores identificaram 19 proteínas-chave no plasma sanguíneo que funcionam como uma impressão digital molecular da doença, detectável com tecnologia ultrassensível em uma única amostra.
- O teste alcança 96% de precisão, determina o estágio da doença e abre caminho para monitorar a eficácia de tratamentos em tempo real.
- A simplicidade do exame torna viável o rastreamento em larga escala, transformando o diagnóstico do Alzheimer de um processo reativo em uma estratégia preventiva.
Pesquisadores da Universidade de Ciência e Tecnologia de Hong Kong desenvolveram um exame de sangue que detecta o Alzheimer com 96% de precisão, potencialmente transformando a forma como a doença é diagnosticada antes que seus efeitos se tornem visíveis.
A equipe partiu de 429 proteínas plasmáticas associadas ao Alzheimer e isolou 19 que formam uma espécie de assinatura molecular da doença. Usando uma tecnologia chamada proximity extension assay — capaz de medir mais de mil proteínas em uma única amostra de plasma —, o teste não apenas confirma a presença da doença, mas também identifica em qual estágio ela se encontra. Essa assinatura existe no sangue muito antes de qualquer perda de memória ou declínio cognitivo.
O que torna a descoberta especialmente relevante é a janela que ela abre. O Alzheimer começa seu trabalho silencioso no cérebro uma ou duas décadas antes dos primeiros sintomas — um período em que intervenções poderiam, em tese, alterar o curso da doença. O estudo contou com colaboração da University College London e parcerias clínicas em dois hospitais de Hong Kong.
Para pacientes e sistemas de saúde, as implicações são profundas. A detecção precoce permite agir enquanto o cérebro ainda acumula danos de forma silenciosa, mas a pessoa permanece cognitivamente intacta. Além disso, a capacidade do teste de rastrear a progressão da doença oferece aos médicos uma ferramenta para monitorar tratamentos com base em mudanças mensuráveis — sem precisar esperar que o declínio cognitivo se torne evidente.
A team at Hong Kong University of Science and Technology has developed a blood test that can identify Alzheimer's disease with 96% accuracy—a finding that could reshape how the condition is diagnosed and monitored in its earliest stages.
The researchers isolated 19 key plasma proteins from a larger pool of 429 candidates associated with Alzheimer's, assembling them into a diagnostic panel that functions as a molecular signature of the disease. This fingerprint exists in the blood long before a patient experiences the memory loss or cognitive decline that typically sends them to a doctor. The test uses proximity extension assay, an ultrasensitive protein detection technology capable of measuring more than 1,000 different proteins in a single plasma sample, allowing clinicians to not only confirm the presence of Alzheimer's but also determine which stage of the disease a patient has reached.
What makes this advance significant is timing. Alzheimer's begins its work in the brain a decade or two before symptoms surface—a window during which intervention might slow or alter the disease's course. Until now, definitive diagnosis required expensive, invasive procedures. This blood test is simple, non-invasive, and accurate enough to screen large populations efficiently. A researcher involved in the work described it as a straightforward diagnostic solution that would facilitate both widespread screening and precise disease staging, opening the door to earlier treatment.
The study emerged from collaboration between the Hong Kong team and researchers at University College London, with clinical partnerships at Prince of Wales Hospital and Queen Elizabeth Hospital. The work represents a convergence of advances in protein detection technology and our growing understanding of Alzheimer's molecular biology—the ability to read the disease's signature in blood before it announces itself through memory loss or confusion.
For patients and families, the implications are substantial. Early detection means the possibility of intervention during the disease's silent phase, when the brain is still accumulating damage but the person remains cognitively intact. For public health systems, a simple blood test opens the possibility of screening at scale, moving Alzheimer's diagnosis from a reactive process—waiting for symptoms to appear—to a proactive one. The test's ability to track disease progression also gives doctors a tool to monitor how treatments are working, adjusting care based on measurable changes in the protein signature rather than waiting for cognitive decline to become obvious.
Citações Notáveis
A simple, non-invasive and accurate diagnostic solution that will facilitate population-wide screening and disease staging— HKUST researcher leading the study
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this test can identify which stage of Alzheimer's someone is in?
Because right now, by the time someone gets diagnosed, they're often already symptomatic—the disease has been working for years. If you can see the stage, you can see how fast it's progressing and whether a treatment is actually slowing it down. That's the difference between guessing and knowing.
The source mentions the disease affects the brain 10 to 20 years before symptoms. That's a long window.
Exactly. That's where the real opportunity is. If you can catch someone in year three or four, before they've lost anything, you might be able to do something about it. Right now, most people don't know they have it until year twelve or fifteen, when damage is already substantial.
Is 96% accuracy high enough for a screening test?
For a blood test, yes—that's very good. It's not perfect, but it's good enough to be useful as a first step. You'd still want confirmation, but you're not going to miss many cases, and you're not going to alarm too many people with false positives.
What changes about how doctors treat Alzheimer's if they can detect it this early?
Everything, potentially. Right now, treatment is mostly about managing symptoms in people who already have them. Early detection lets you think about prevention or slowing progression before symptoms start. It's the difference between treating a fire and preventing one.
The test looks at 19 proteins out of 429 they found. Why those 19?
They're the ones that best predict Alzheimer's—the ones that together form a reliable signature. It's like finding the essential ingredients in a recipe instead of listing every spice in the kitchen.